DEC 31, 2015 09:08 AM PST

World's First Dengue Fever Vaccine Approved in 3 Countries

Dengue fever is a mosquito-borne disease that’s prevalent in tropical locations like Latin America, Southeast Asia, and the Pacific islands. Up until now there was no vaccine against the dengue virus. But the first ever developed vaccine has swiftly gotten approval in three countries, with more approvals expected soon.
Mosquito-borne disease affecting millions has had no approved vaccine until now
The vaccine against the dengue virus, Dengvaxia, was developed and is manufactured by the French pharmaceutical giant Sanofi.
"It's a major step in the prevention of dengue and for public health," Olivier Charmeil, head of Sanofi's vaccines division, said in a statement.
Dengue fever is caused by any one of four related dengue virus that’s transmitted through mosquito bites. Once infected sufferers experience painful flu-like symptoms that, in severe cases, have the potential to cause life-threatening dengue hemorrhagic fever or dengue shock syndrome. The Centers for Disease Control and Prevention estimates that as many as 400 million people are infected yearly; about 22,000 people die from it.

The Dengvaxia vaccine is actually based on an attenuated form of the yellow fever virus. This is because both viruses are very similar, sharing the same Genus. Geneticists then tweaked the yellow fever virus version to make it express the four types of dengue proteins. Once immunized with this modified virus, the host should be able to make antibodies against all four forms of dengues. Reportedly, Sanofi's research and development on the Dengvaxia vaccine took 2 decades and cost in excess of $1.6 billion.
Mexico was the first to approve the vaccine on December 11, 2015. Then last week on December 22, 2015 Philippines became the first Asian country to approve the vaccine. Dengvaxia recently secured the green light in another country: Brazil, where over 1.4 million cases of dengue fever were reported in 2015 alone. The vaccine is currently being reviewed in about 20 other countries in Asia and Latin America.

The United States had it’s own scare with Dengue fever earlier this year when cases appeared in Hawaii and Florida. In Puerto Rico the disease is already considered endemic.
Dengvaxia is a not a flawless vaccine. Clinical trials show that it works to prevent the disease in about 60% of cases; this means that the vaccine has a one third chance of being ineffective. Furthermore, the efficacy of the vaccine is restricted to people between 9 to 45 years old. This excludes young children and the elderly, arguably the populations most at risk who need a dengue vaccine the most. But an imperfect vaccine may be better than no vaccine at all.

Sources: Scientific American, Yahoo News
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at
You May Also Like
DEC 03, 2018
DEC 03, 2018
Alcohol Consumption: How Much Is Too Much for the Heart?
  Arteries stiffen over time as a result of aging, but heavy alcohol drinking habits over a lifetime can accelerate arterial aging, especially in men....
JUN 05, 2018
Clinical & Molecular DX
JUN 05, 2018
"ImmunoPET" Imaging Identifies IBD Inflammation
Scientists are now applying PET imaging to detect inflammation in people with inflammatory bowel disease (IBD). This could help countless IBD patients conn...
AUG 08, 2018
AUG 08, 2018
Use of Probiotics Linked to Severe Bloating, Brain Fog
Gut bacteria can have a powerful effect on brain function....
SEP 24, 2018
Genetics & Genomics
SEP 24, 2018
Towards a Blood Test for Drowsy Driving
Driving is an everyday activity for many people around the world, and it comes with serious risks....
NOV 17, 2018
Genetics & Genomics
NOV 17, 2018
Joubert Syndrome Model Successfully Treated with Gene-editing
A life-threatening kidney disease may be one day be a treatable condition thanks to new work by researchers, and patients with the illness....
DEC 04, 2018
DEC 04, 2018
Natural HIV Resistance
A team of scientists discover unique immune reactions to the one percent of HIV infected patients that are able to fend off viral propagation without antiretroviral therapy...
Loading Comments...